Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #856 on Merck and Co Inc (MRK)
DewDiligence
08/01/23 5:43 PM
#860 RE: DewDiligence #856
Merck & Co raised its full-year revenue forecast on Tuesday as second-quarter sales of its top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil, sailed past Wall Street estimates. Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion. …Sales of Gardasil…surged 47% to $2.5 billion, also well above Wall Street estimates of $2.1 billion.